National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead, Sydney, Australia.
Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2.
Hib-primed but MenC-naive toddlers (N = 433) were randomized to receive 1 dose of Hib-MenC-TT or separate Hib-TT and MenC-CRM197 vaccines. One month later, noninferiority was demonstrated for serum bactericidal anti-MenC antibodies (rSBA) and Hib antipolyribosylribitol phosphate (PRP) antibodies; >99% in both groups had rSBA titer ≥ 8 or anti-PRP concentration ≥ 0.15 μg/mL. After 12 months, rSBA titer ≥ 8 persisted in 86.7% and 76.4%, and anti-PRP concentration ≥ 0.15 μg/mL persisted in 98.8% and 100% of children, respectively.
Hib 初免但 MenC 初免婴儿（N = 433）随机接受 1 剂 Hib-MenC-TT 或 Hib-TT 和 MenC-CRM197 疫苗分开接种。1 个月后，血清杀菌抗 MenC 抗体（rSBA）和 Hib 抗多聚核糖醇磷酸（PRP）抗体均显示非劣效性；两组均有＞99%的儿童 rSBA 滴度≥8 或抗 PRP 浓度≥0.15μg/ml。12 个月后，rSBA 滴度≥8 的分别持续存在于 86.7%和 76.4%的儿童，抗 PRP 浓度≥0.15μg/ml 的分别持续存在于 98.8%和 100%的儿童。
